Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZURA
SELLZura Bio Limited · Healthcare · United States · $496M · Avg Vol: $7M/d
22
StockRankGet insider-trade alerts
Q
33
V
30
M
46
P/E (TTM)
—
ROE
-41.0%
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)+45.4%
SMA 50SMA 200
Close
$5.38
RSI (14)
55.3
52W High
$7.44
From 52W High
0.7%
SCORE BREAKDOWN
Quality
33
ROIC
-80.3%8.6
ROE
-41.0%21.7
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-63.8%3.6
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.00x97.8
Current Ratio
19.33x95.1
Value
30
P/E (TTM)
—N/A
EV/EBITDA
-3.3x25.0
P/FCF
—N/A
P/B
2.3x54.8
P/S
—N/A
Div Yield
—N/A
Momentum
46
52W High %
72%57.9
RS 6M
-23%40.5
SMA 50/200
0.92x46.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+49%54.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$496M
P/E (Forward)
-9.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZURA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZURA | Zura Bio Limited(you) | $496M | 22 | SELL |
| ASMB | Assembly Biosciences, Inc. | $506M | 23 | SELL |
| RZLT | Rezolute, Inc. | $480M | 23 | SELL |
| ARVN | Arvinas, Inc. | $518M | 20 | STRONG SELL |
| LRMR | Larimar Therapeutics, Inc. | $416M | 23 | SELL |
| ARTV | Artiva Biotherapeutics, Inc. | $487M | 26 | SELL |
| BNTC | Benitec Biopharma Inc. | $394M | 24 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $609M | 25 | SELL |
| ENTA | Enanta Pharmaceuticals, Inc. | $372M | 23 | SELL |
| FDMT | 4D Molecular Therapeutics, Inc. | $526M | 28 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%